Two Sigma Investments LP Has $211,000 Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Two Sigma Investments LP trimmed its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 24.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 145,238 shares of the company’s stock after selling 48,021 shares during the quarter. Two Sigma Investments LP’s holdings in Compass Therapeutics were worth $211,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of CMPX. Tang Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC grew its holdings in Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after acquiring an additional 9,451 shares during the last quarter. MPM Bioimpact LLC grew its stake in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $11,293,000. Finally, DAFNA Capital Management LLC raised its position in Compass Therapeutics by 35.5% in the 4th quarter. DAFNA Capital Management LLC now owns 158,394 shares of the company’s stock worth $230,000 after purchasing an additional 41,512 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Guggenheim decreased their price objective on Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target on the stock. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.13.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Anderman bought 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00% increase in their position. The disclosure for this purchase can be found here. Company insiders own 29.80% of the company’s stock.

Compass Therapeutics Trading Down 0.8%

Shares of CMPX opened at $2.41 on Friday. The stock has a market cap of $333.26 million, a P/E ratio of -6.51 and a beta of 1.41. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The stock’s 50-day moving average price is $1.98 and its two-hundred day moving average price is $2.18.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). As a group, equities analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.